

REFERENCES

- Agrawal S. and Panchagula R. 2004. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage form. *Pharmazie*, 59: 775–781.
- Allinson G. J., Dansereau J. R. and Sakr A. 2001. The effects of packaging on stability of a moisture sensitive compound. *Int J. Pharm.*, 221:49–56.
- Amidon E. G. and Middleton R. K. 1988. Accelerated physical stability testing and long-term predictions of changes in the crushing strength of tablets stored in blister packages. *Int J. Pharm.*, 45:79–89.
- Bain F.D., Munday L.D. and Cox J.P. 1998. Evaluation of biodegradable rifampicin bearing microsphere formulations using a stability-indicating high-performance liquid chromatographic assay. *Eur. J. Pharm. Sci.*, 7:57–65.
- Bhutani H., Mariappan T.T. and Singh S. 2003. Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and presence of light. 2. Packaged and unpackaged antituberculosis drug products. *Pharm. Tech.*, June:44–52.
- Bhutani H., Mariappan T.T. and Singh S. 2004. Explanation for the physical instability of a marketed fixed-dose combination (FDC) formulation containing isoniazid and ethambutol and proposed solution. *Drug Dev. Ind. Pharm.* 30(6): 667–672.
- Bhutani H., Mariappan T.T. and Singh S. 2004. The physical and chemical stability of anti-tuberculosis fixed dose combination products under accelerated climatic condition. *Int. J. Tuberc. Lung Dis.*, 8(9): 1073–1080.
- Bhutani H., Singh S., Jindal C.K. and Chakraborti K.A. 2005. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. *J Pharm. and Biomed. Anal.* 39(5): 892–899.

- Brennan J.P. 2003. Structure, function, and biogenesis of the cell wall of *Mycobacterium tuberculosis*. *Tuberc.*, 83: 91–97.
- Brewer A.G. 1977. Isoniazid. Analytical Profiles of Drug Substances. Academic press, New York. 5: 183–258.
- British Pharmacopoeial Commission. 2001. British Pharmacopoeia. London: The Stationary Office Ltd.
- Bureau of India. India. Available from :URL:<http://www.pharmabiz.com>.
- Carlin A., Gregory N. and Simmons J. 1998. Stability of isoniazid in isoniazid syrup: formation of hydrazine. *J Pharm Bio Anal.*, 17: 885–890.
- Cartensen T.J. 1990. Solution Kinetics. Marcel Dekker Inc., New York.
- Crespo D. L. M. and Alvarez R. S. 1985. Metodos non isotermicos en la prediccion de la estabilidad de los medicamentos. Revision bibliografica. *Rev Cub Farm.*, 19:443–449.
- Degim Z. and Agabeyoglu I. 2002. Nonisothermal stability tests of famotidine and nizatidine. *IL Farmaco.*, 57: 729–735.
- El-Bary A.A., Nour S.A., Soliman I.I. and Sabri N.A. 2004. A stability study of rifampicin. *Bulletin of the faculty of pharmacy (Cairo University)*, 42(2): 69–83.
- Foye O.W., Lemke L.T. and Williams A.D. 1995. Antimycobacterial agents. Principles of Medicinal Chemistry, 4th edition, Williams and Wilkins, Pennsylvania.
- Felder E. and Pitre D. 1983 Pyrazinamide. Analytical Profiles of Drugs Substance. Academic press, New York. 433–461.

- Frieden R.T., Sterling R.T., Munsiff S.S., Watt J.C. and Dye C. 2003. Tuberculosis. *Lancet*, 362: 887–899.
- Galway K.A. 2003. Eradicating erroneous Arrhenius arithmetic. *Thermochimica.*, 399: 1–29.
- Gallo G.G. and Radaelli P.1976. Rifampicin. Analytical Profiles of Drug Substances. Academic press, New York. 5: 468–513.
- Global Tuberculosis Control. 2005. WHO Report, Country Profile, Thailand, 113–115. Available from :URL:http://www.who.int/tb/publications/global_report/2005/pdf/Thailand.pdf.
- Guangrong N. 1982. Refrigeration of rifampicin. *Yaoxue Tongbao.*, 97: 11763. (In Chinese).
- Health Information Group. 2003. Bureau of Health Policy and Strategy. 115. Available from :URL:http://203.157.19.191/conference_46.pdf.
- Hempenstall J. M., Irwin W. J., Po A. L. W. and Andrews A. H. 1983. Nonisothermal kinetics using a microcomputer: a derivative approach to the prediction of the stability of penicillin formulations. *J. Pharm Sci.*, 72: 668–673.
- ICH Steering Committee. 2003. ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances and Products Q1A(R2).
- Institute of Community Medicine, Madras Medicine Homepage. 2006. Available from :URL:<http://www.icm.tn.gov.in/drug%20formulary/ANTIINFECTIVE%20DRUGS.htm>.
- IPCS Homepage. Available from :URL:[http://www.rifampicin \(PIM 472\).htm](http://www.rifampicin (PIM 472).htm).

IPCS Homepage. Available from :URL:[http://www.isoniazid \(PIM 288\).htm](http://www.isoniazid (PIM 288).htm).

Jenkins A. W. and Osborn R. K. 1993. Packaging Drugs and Pharmaceutical. Technomic press, Pennsylvania.

Kipp E. J. 1985. Nonisothermal kinetics- comparison of two methods of data treatment.

Int J. Pharm., 26: 339-354.

Klopman G., Fercu D. and Jacob J. 1996. Computer-aided study of the relationship between structure and antituberculosis activity of a series of isoniazid derivatives. *Chem Phys.*, 204(2-3): 181-193.

Laserson K.F., Kenyon T.A., Layloff T. and Binkin N.J. 2001. Substandard tuberculosis drugs on the global market and their simple detection. *Int. J. Tuberc. Lung Dis.*, 5 (5): 448-454.

Lei B., Wei J.C. and Tu C.S. 2000. Action mechanism of antitubercular isoniazid : activation by mycobacterium tuberculosis kat G, isolation and characterization of Inh A inhibitor. *J. Bio. Chem.*, 275(4): 2520-2526.

Ramalho C.T., da Cunha F.F.E. and de Alencastro B.R. 2004. A density functional study on the complexation of ethambutol with divalent cations. *J. Mol. Str. (Theochem)*, 676: 149-153.

Rookkapan K. 2001. Problem of anti-tuberculosis drug management in southern Thailand. In Abstract of The 17th Annual Academic Meeting, Faculty of Medicine., Hat Yai, Songkhla, 15-17 August.

Sankar R., Shaed N. and Singh S. 2003. Behavior of decomposition of rifampicin in presence of isoniazid in the pH range 1-3. *Drug Dev. and Ind. Pharm.*, 7: 733-738.

- Singh S., Bhutani H., Mariappan T.T., Kaur H., Bajaj M. and Pakhale S. 2002. Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and presence of light. 1. Pure anti-tuberculosis drugs and their combinations. *Int. J. Pharm.*, 245(1-2): 37-44.
- Singh S., Mariappan T.T., Sharda N., Kumer S. and Chakraborti A.K. 2000. The reason for an increases in decomposition of rifampicin in the presence of isoniazid under acid condition. *Pharm. and Pharmaco.Cmm.*, 6 (9): 405-410.
- Singh S. and Mohan B. 2003. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products. *Int. J. Tuber. Lung Dis.*, 7(3): 298-303.
- Singh S. 2004. Tuberculosis. *Curr. Anaes. & Crit. Care*, 15: 165-171.
- Sho I. 1971. Stability of isoniazid and its related compounds V. oxidative degradation of isoniazid. *Yakugaku Zasshi*, 91(1): 81-87.
- Speight G.J. 2005. Lange's Handbook of Chemistry. 16th ed McGraw Hill, New York.
- The United States Pharmacopeial Convention. 2000. The United States Pharmacopeia 24 and National Formulary 19. Asian edition. India: Tata Donnelley Ltd.
- Tucker I. 1985. Nonisothermal stability testing. *Pharm. Techol.*, 68-78.
- Tucker I. G. and Owen W. R. 1982. Estimation of all parameter from nonisothermal kinetic data. *J. Pharm. Sci.*, 71:969-974.
- Vyazovkin S. and Wight A. C. 1999. Model-free and model-fitting approaches to kinetic analysis of isothermal and nonisothermal data. *Thermo Acta.*, 340-341: 53-68.
- Waterman C.K. and Adami C.R. 2005. Accelerated aging: Prediction of chemical stability of pharmaceuticals. *Int. J. Pharm.*, 293: 101-125.

- Wang, D.P. 2002. Epidemiology and control of tuberculosis in Taipei, *J. Infect.*, 45: 82–87.
- Woff E.M. 1994. Antimycobacterial agents. Burger's Medicinal Chemistry and Drug Discovery, 5th edition, volume 2: Therapeutic agents. John Wiley & Sons Inc. New York.
- Yepes F.J., Sullivan J. and Pinto A. 2004. Tuberculosis: medical management update. *Oral Surg., Oral Med., Oral Path., Oral Rad. and Endodontology.* 98: 267–273.
- Yoshioka S., Aso Y. and Uchiyama M. 1987. Statistical evaluation of nonisothermal prediction of drug stability. *J Pharm. Sci.*, 76:794–798.
- Yoshioka S. and Carstensen T.J. 1990. Rational storage conditions for accelerated testing of stability of solid pharmaceuticals. *J. Pharm. Sci.*, 79(10): 943–944.
- Zhan X., Yen G., Wang L. and Ma B. 1997. Exponential heating in drug stability experimental and statistical evaluation of nonisothermal and isothermal prediction. *J. Pharm. Sci.*, 86:709–715.
- Zhan X., Yen G. and Ma B. 1997. Determination of rate order for degradation of drugs with nonisothermal stability experiment. *J. Pharm. Sci.*, 86:1099–1104.
- Zhang Y., Wade M.M., Scorpio A., Zhang H. and Sun Z. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. *J. Antimicro. Chemo.*, 52:790–795.